Vimta Labs Limited (NSE:VIMTALABS)
India
· Delayed Price · Currency is INR | Market Cap | 22.64B |
| Revenue (ttm) | 3.53B |
| Net Income (ttm) | 613.74M |
| Shares Out | n/a |
| EPS (ttm) | 27.30 |
| PE Ratio | 36.88 |
| Forward PE | n/a |
| Dividend | 2.00 (0.20%) |
| Ex-Dividend Date | Jul 11, 2024 |
| Volume | 137,735 |
| Average Volume | 228,407 |
| Open | 1,048.00 |
| Previous Close | 998.90 |
| Day's Range | 999.05 - 1,048.00 |
| 52-Week Range | 420.00 - 1,178.00 |
| Beta | 0.17 |
| RSI | 50.94 |
| Earnings Date | May 13, 2025 |
About Vimta Labs
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, central lab, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to supp... [Read more]
Financial Performance
In 2023, Vimta Labs's revenue was 3.19 billion, an increase of 0.08% compared to the previous year's 3.19 billion. Earnings were 410.09 million, a decrease of -14.87%.
Financial StatementsNews
Vimta Labs shares surge 34% in past one month
Vimta Labs has been a standout performer in the stock market, with its shares surging 34% over the past month. The stock hit a 52-week high of ₹980.75 on December 6, 2024, reflecting strong investor i...